Black Rock Inc. Nymox Pharmaceutical Corp Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.19 - $0.49 $18,415 - $47,492	-96,923 Reduced 71.47%	38,689 $7,000
Q1 2023 May 12, 2023	BUY	$0.33 - $0.5 $1,292 - $1,959	3,918 Added 2.98%	135,612 $46,000
Q4 2022 Feb 13, 2023	BUY	$0.28 - $0.74 $731 - $1,932	2,612 Added 2.02%	131,694 $42,000
Q3 2022 Nov 14, 2022	SELL	$0.22 - $0.61 $718 - $1,991	-3,265 Reduced 2.47%	129,082 $53,000
Q2 2022 Aug 12, 2022	SELL	$0.38 - $1.41 $1,192 - $4,424	-3,138 Reduced 2.32%	132,347 $58,000
Q1 2022 May 12, 2022	SELL	$1.21 - $2.0 $211 - $350	-175 Reduced 0.13%	135,485 $171,000
Q4 2021 Feb 10, 2022	SELL	$0.95 - $2.1 $1,907 - $4,216	-2,008 Reduced 1.46%	135,660 $176,000
Q3 2021 Nov 09, 2021	SELL	$1.3 - $2.23 $28,596 - $49,053	-21,997 Reduced 13.78%	137,668 $283,000
Q2 2021 Aug 11, 2021	BUY	$1.46 - $2.48 $233,110 - $395,969	159,665 New	159,665 $252,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.